About one-third of people with depression do not find relief from current treatments, resulting in significant personal and economic costs. Professor Itamar Grotto, chairman of PsyRx, emphasizes the urgent need to prioritize mental health within healthcare. PsyRx, newly listed on the Tel Aviv Stock Exchange, is developing a new therapy for treatment-resistant depression using a controlled dose of a psychoactive compound. This innovative approach aims to enhance the effectiveness of existing antidepressants, offering hope for faster and longer-lasting results in a field that has seen little progress.